secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950103-23-016146
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q3 2023 loss per share $0.08; FDA agrees PRGN-2012 study pivotal for BLA
--------------------------------------------------------------------------------

- Cash and investments $79.0M as of Sep 30, 2023; cash runway projected into 2025.
- Total revenues decreased 92% to $1.3M in Q3 2023 from $16.6M in Q3 2022, largely from prior-year non-cash collaboration revenue.
- Loss from continuing operations $19.8M ($0.08 per share) vs. $7.6M ($0.04) in Q3 2022.
- FDA agreed ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as pivotal for accelerated BLA; Phase 2 enrollment complete, expected completion Q2 2024.
- SG&A costs down 9% in Q3 and 17% for first nine months 2023 vs. prior year, driven by reduced professional fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/0000950103-23-016146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323016146/dp202678_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-016146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer